3/14
01:32 am
msle
Medium
Report
3/11
08:03 am
msle
Satellos Bioscience (MSLE) is now covered by Cantor Fitzgerald. They set an "overweight" rating on the stock.
Medium
Report
Satellos Bioscience (MSLE) is now covered by Cantor Fitzgerald. They set an "overweight" rating on the stock.
3/10
07:37 am
msle
Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference [Yahoo! Finance]
High
Report
Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference [Yahoo! Finance]
3/10
07:00 am
msle
Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference
High
Report
Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference
2/24
07:00 am
msle
Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
Low
Report
Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
2/18
07:00 am
msle
Satellos to Host Virtual KOL Event on SAT-3247 in Duchenne Muscular Dystrophy
Low
Report
Satellos to Host Virtual KOL Event on SAT-3247 in Duchenne Muscular Dystrophy
2/17
07:00 am
msle
Satellos to Participate in Upcoming Investor Conferences
Low
Report
Satellos to Participate in Upcoming Investor Conferences
2/12
06:38 pm
msle
Satellos Bioscience (NASDAQ:MSLE) is now covered by analysts at
Weiss Ratings. They set a "sell (d-)" rating on the stock.
Low
Report
Satellos Bioscience (NASDAQ:MSLE) is now covered by analysts at
Weiss Ratings. They set a "sell (d-)" rating on the stock.
2/12
07:00 am
msle
Satellos Announces First Participant Dosed in Phase 2 Pediatric Study of SAT-3247 for Duchenne Muscular Dystrophy
Medium
Report
Satellos Announces First Participant Dosed in Phase 2 Pediatric Study of SAT-3247 for Duchenne Muscular Dystrophy
2/12
06:37 am
msle
Satellos Bioscience (NASDAQ:MSLE) was upgraded by analysts at Zacks Research to a "hold" rating.
Medium
Report
Satellos Bioscience (NASDAQ:MSLE) was upgraded by analysts at Zacks Research to a "hold" rating.
2/10
07:00 am
msle
Satellos to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit 2026
Medium
Report
Satellos to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit 2026
2/9
05:48 pm
msle
Satellos Closes US$57.2 Million Public Offering in Canada and the United States [Yahoo! Finance]
Medium
Report
Satellos Closes US$57.2 Million Public Offering in Canada and the United States [Yahoo! Finance]
2/9
05:00 pm
msle
Satellos Closes US$57.2 Million Public Offering in Canada and the United States, Including Exercise of Underwriters’ Option to Purchase Additional Shares
Low
Report
Satellos Closes US$57.2 Million Public Offering in Canada and the United States, Including Exercise of Underwriters’ Option to Purchase Additional Shares
2/6
08:30 am
msle
Satellos Announces Pricing of US$50 Million Public Offering in Canada and the United States
Medium
Report
Satellos Announces Pricing of US$50 Million Public Offering in Canada and the United States